Here are the results of our 'design space' poll.
PharmTech Poll Results: How do you define ‘design space’?
Thanks to all of you who participated in our poll! Here are a few of your answers, followed by the definition of ‘design space’ given by the FDA.
Your answers
1. “The multidimensional ‘space’ is defined by the extreme combinations of all operating parameters for process, equipment, and facilities. Narrow design space by identifying critical (direct impact) or key (indirect impact) parameters on critical to quality product attributes.”
2. “The mathematical and statistical equations defining the combination of independent factor space and dependent response space from designed experiments that results in a system, product or process that consistently meets its quality characteristics with a high degree of assurance.”
3. “I think ‘design space’ is just a new buzz word for defining the acceptable range of a product and process, which is something an optimization program should have done for many years now.”
4. “The multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters associated with a high probability of the critical quality attributes all meeting specification. Mathematically, it is: Design Space={x such that Prob(Y is in S given x) is at least some acceptable reliability value}, where Y is a vector of critical quality attributes, S is a multidimensional specification region, and x is a vector of controllable process parameters. See Peterson, J. J. (2004) Journal of Quality Technology, 139-153, Figure 6.”
According to FDA
FDA defines design space in its Guidance for Industry Q8: Pharmaceutical Development, as:
“The multidimensional combination and interaction of input variables (e.g., material attributes) and process parameters that have been demonstrated to provide assurance of quality. Working within the design space is not considered as a change. Movement out of the design space is considered to be a change and would normally initiate a regulatory postapproval change process. Design space is proposed by the applicant and is subject to regulatory assessment and approval.” The guidance is available here.
To add your definition, click here.
To answer our next question, “How do you define ‘PAT’?,” click here.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.